A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

NCT07708753 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

460

Enrollment

INDUSTRY

Sponsor class

Conditions

Platinum-resistant Ovarian Cancer
Platinum-resistant Primary Peritoneal Cancer
Platinum-resistant Fallopian Tube Cancer

Interventions

DRUG: SYS6043
DRUG: Liposomal doxorubicin, paclitaxel, or topotecan

Sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd.